S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55

Strongbridge Biopharma Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00%)
(As of 10/5/2021)
Today's Range
50-Day Range
52-Week Range
684,684 shs
Average Volume
866,464 shs
Market Capitalization
$135.66 million
P/E Ratio
Dividend Yield

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Strongbridge Biopharma logo

About Strongbridge Biopharma

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.


Tudor Capital Europe LLP : Form 8.3 - Strongbridge Biopharma Plc
June 29, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$30.73 million
Book Value
$0.98 per share


Net Income
$-45.08 million
Net Margins
Pretax Margin




Free Float
Market Cap
$135.66 million

Company Calendar

Last Earnings


Overall MarketRank

1.63 out of 5 stars

Medical Sector

1016th out of 1,414 stocks

Pharmaceutical Preparations Industry

494th out of 682 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Strongbridge Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SBBP, but not buy additional shares or sell existing shares.
View analyst ratings for Strongbridge Biopharma
or view top-rated stocks.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%.
View Strongbridge Biopharma's earnings history

What price target have analysts set for SBBP?

3 Wall Street analysts have issued 1-year price targets for Strongbridge Biopharma's shares. Their forecasts range from $3.25 to $10.00. On average, they expect Strongbridge Biopharma's stock price to reach $6.63 in the next twelve months. This suggests a possible upside of 231.3% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • John H. Johnson, Chief Executive Officer & Director
  • Richard S. Kollender, President & Chief Financial Officer
  • Fredric Cohen, Chief Medical Officer
  • Brian Conner, Chief Compliance Officer
  • Peter J. Valentinsson, Senior Vice President-Global Technical Operations

What other stocks do shareholders of Strongbridge Biopharma own?

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.00.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45.08 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Where are Strongbridge Biopharma's headquarters?

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at (610) 254-9200 or via email at [email protected].

This page was last updated on 1/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.